Skip to main content

Natera

Natera, Inc. is an American diagnostics company specializing in cell-free DNA testing and non-invasive genetic analytics. The company develops and commercializes molecular diagnostic services across women's health, oncology, and organ health, including non-invasive prenatal screening, carrier screening, liquid biopsy tumor tracking, and organ transplant rejection assessment. Its primary revenue drivers stem from reimbursement payments by commercial health insurers, government healthcare programs, and individual patients for diagnostic test volume processing. Natera holds a leading market position in non-invasive prenatal testing with its Panorama screen, while expanding footprint in oncology with its Signatera molecular residual disease test. The company primarily targets clinical healthcare providers, OB-GYNs, oncologists, and transplant centers in the United States. Corporate headquarters are situated in Austin, Texas, United States. Natera's common stock is listed on the Nasdaq Global Select Market.

46 of the funds FundTelligence covers report a position in Natera.

Legal name
Natera Inc.
Sector
Health Care
Country
United States
Funds holding it
46
Exposure themes
Diagnostics and screening, Genetic Testing, Maternal & Prenatal Health, Molecular Diagnostics, Precision Medicine & Genomics, Prenatal Testing, Prevention, Women's Health

Funds holding Natera

Showing the 8 largest of 46 funds holding it.

Loading...